Cancer Targeted Therapy-EMEA Market Status and Trend Report 2013-2023
Report Summary
Cancer Targeted Therapy-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Targeted Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Cancer Targeted Therapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Targeted Therapy in EMEA, with company and product introduction, position in the Cancer Targeted Therapy market
Market status and development trend of Cancer Targeted Therapy by types and applications
Cost and profit status of Cancer Targeted Therapy, and marketing status
Market growth drivers and challenges
The report segments the EMEA Cancer Targeted Therapy market as:
EMEA Cancer Targeted Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Cancer Targeted Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Tumor Antigens As Targets of Antibodies
Development of Antibodies for Clinical Purposes
Complement Dependent Cytotoxicity (CDC)
Signal Transduction Changes
EMEA Cancer Targeted Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Other
EMEA Cancer Targeted Therapy Market: Players Segment Analysis (Company and Product introduction, Cancer Targeted Therapy Sales Volume, Revenue, Price and Gross Margin):
Advaxis
Bind Therapeutics
Boehringer Ingelheim
Bristol Mayer Squibb
Celldex Therapeutics
Dendreon Corporation
Eli Lily
GalaxoSmithKline
Galena Biopharma
Genetech
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
Johnson & Johnson
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Merck
Novartis
Peregrine Pharmaceuticals
Pfizer
Roche
Sanofi
Seattle Genetics
Teva
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Cancer Targeted Therapy-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Cancer Targeted Therapy industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Whole EMEA and Regional Market Size of Cancer Targeted Therapy 2013-2017, and development forecast 2018-2023
Main market players of Cancer Targeted Therapy in EMEA, with company and product introduction, position in the Cancer Targeted Therapy market
Market status and development trend of Cancer Targeted Therapy by types and applications
Cost and profit status of Cancer Targeted Therapy, and marketing status
Market growth drivers and challenges
The report segments the EMEA Cancer Targeted Therapy market as:
EMEA Cancer Targeted Therapy Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
Europe
Middle East
Africa
EMEA Cancer Targeted Therapy Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Tumor Antigens As Targets of Antibodies
Development of Antibodies for Clinical Purposes
Complement Dependent Cytotoxicity (CDC)
Signal Transduction Changes
EMEA Cancer Targeted Therapy Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Hospital
Clinic
Other
EMEA Cancer Targeted Therapy Market: Players Segment Analysis (Company and Product introduction, Cancer Targeted Therapy Sales Volume, Revenue, Price and Gross Margin):
Advaxis
Bind Therapeutics
Boehringer Ingelheim
Bristol Mayer Squibb
Celldex Therapeutics
Dendreon Corporation
Eli Lily
GalaxoSmithKline
Galena Biopharma
Genetech
ImmunoCellular Therapeutics
ImmunoGen
Inovio Pharmaceuticals
Johnson & Johnson
NeoStem Oncology
NewLink Genetics
Northwest Biotherapeutics
Merck
Novartis
Peregrine Pharmaceuticals
Pfizer
Roche
Sanofi
Seattle Genetics
Teva
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF CANCER TARGETED THERAPY
1.1 Definition of Cancer Targeted Therapy in This Report
1.2 Commercial Types of Cancer Targeted Therapy
1.2.1 Tumor Antigens As Targets of Antibodies
1.2.2 Development of Antibodies for Clinical Purposes
1.2.3 Complement Dependent Cytotoxicity (CDC)
1.2.4 Signal Transduction Changes
1.3 Downstream Application of Cancer Targeted Therapy
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Other
1.4 Development History of Cancer Targeted Therapy
1.5 Market Status and Trend of Cancer Targeted Therapy 2013-2023
1.5.1 EMEA Cancer Targeted Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Targeted Therapy Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Cancer Targeted Therapy in EMEA 2013-2017
2.2 Consumption Market of Cancer Targeted Therapy in EMEA by Regions
2.2.1 Consumption Volume of Cancer Targeted Therapy in EMEA by Regions
2.2.2 Revenue of Cancer Targeted Therapy in EMEA by Regions
2.3 Market Analysis of Cancer Targeted Therapy in EMEA by Regions
2.3.1 Market Analysis of Cancer Targeted Therapy in Europe 2013-2017
2.3.2 Market Analysis of Cancer Targeted Therapy in Middle East 2013-2017
2.3.3 Market Analysis of Cancer Targeted Therapy in Africa 2013-2017
2.4 Market Development Forecast of Cancer Targeted Therapy in EMEA 2018-2023
2.4.1 Market Development Forecast of Cancer Targeted Therapy in EMEA 2018-2023
2.4.2 Market Development Forecast of Cancer Targeted Therapy by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Cancer Targeted Therapy in EMEA by Types
3.1.2 Revenue of Cancer Targeted Therapy in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Cancer Targeted Therapy in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Cancer Targeted Therapy in EMEA by Downstream Industry
4.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Europe
4.2.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Middle East
4.2.3 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Africa
4.3 Market Forecast of Cancer Targeted Therapy in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER TARGETED THERAPY
5.1 EMEA Economy Situation and Trend Overview
5.2 Cancer Targeted Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 CANCER TARGETED THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Cancer Targeted Therapy in EMEA by Major Players
6.2 Revenue of Cancer Targeted Therapy in EMEA by Major Players
6.3 Basic Information of Cancer Targeted Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Cancer Targeted Therapy Major Players
6.3.2 Employees and Revenue Level of Cancer Targeted Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CANCER TARGETED THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Advaxis
7.1.1 Company profile
7.1.2 Representative Cancer Targeted Therapy Product
7.1.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Advaxis
7.2 Bind Therapeutics
7.2.1 Company profile
7.2.2 Representative Cancer Targeted Therapy Product
7.2.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bind Therapeutics
7.3 Boehringer Ingelheim
7.3.1 Company profile
7.3.2 Representative Cancer Targeted Therapy Product
7.3.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.4 Bristol Mayer Squibb
7.4.1 Company profile
7.4.2 Representative Cancer Targeted Therapy Product
7.4.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bristol Mayer Squibb
7.5 Celldex Therapeutics
7.5.1 Company profile
7.5.2 Representative Cancer Targeted Therapy Product
7.5.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
7.6 Dendreon Corporation
7.6.1 Company profile
7.6.2 Representative Cancer Targeted Therapy Product
7.6.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.7 Eli Lily
7.7.1 Company profile
7.7.2 Representative Cancer Targeted Therapy Product
7.7.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Eli Lily
7.8 GalaxoSmithKline
7.8.1 Company profile
7.8.2 Representative Cancer Targeted Therapy Product
7.8.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of GalaxoSmithKline
7.9 Galena Biopharma
7.9.1 Company profile
7.9.2 Representative Cancer Targeted Therapy Product
7.9.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Galena Biopharma
7.10 Genetech
7.10.1 Company profile
7.10.2 Representative Cancer Targeted Therapy Product
7.10.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Genetech
7.11 ImmunoCellular Therapeutics
7.11.1 Company profile
7.11.2 Representative Cancer Targeted Therapy Product
7.11.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoCellular Therapeutics
7.12 ImmunoGen
7.12.1 Company profile
7.12.2 Representative Cancer Targeted Therapy Product
7.12.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoGen
7.13 Inovio Pharmaceuticals
7.13.1 Company profile
7.13.2 Representative Cancer Targeted Therapy Product
7.13.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Inovio Pharmaceuticals
7.14 Johnson & Johnson
7.14.1 Company profile
7.14.2 Representative Cancer Targeted Therapy Product
7.14.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.15 NeoStem Oncology
7.15.1 Company profile
7.15.2 Representative Cancer Targeted Therapy Product
7.15.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of NeoStem Oncology
7.16 NewLink Genetics
7.17 Northwest Biotherapeutics
7.18 Merck
7.19 Novartis
7.20 Peregrine Pharmaceuticals
7.21 Pfizer
7.22 Roche
7.23 Sanofi
7.24 Seattle Genetics
7.25 Teva
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER TARGETED THERAPY
8.1 Industry Chain of Cancer Targeted Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER TARGETED THERAPY
9.1 Cost Structure Analysis of Cancer Targeted Therapy
9.2 Raw Materials Cost Analysis of Cancer Targeted Therapy
9.3 Labor Cost Analysis of Cancer Targeted Therapy
9.4 Manufacturing Expenses Analysis of Cancer Targeted Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER TARGETED THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
1.1 Definition of Cancer Targeted Therapy in This Report
1.2 Commercial Types of Cancer Targeted Therapy
1.2.1 Tumor Antigens As Targets of Antibodies
1.2.2 Development of Antibodies for Clinical Purposes
1.2.3 Complement Dependent Cytotoxicity (CDC)
1.2.4 Signal Transduction Changes
1.3 Downstream Application of Cancer Targeted Therapy
1.3.1 Hospital
1.3.2 Clinic
1.3.3 Other
1.4 Development History of Cancer Targeted Therapy
1.5 Market Status and Trend of Cancer Targeted Therapy 2013-2023
1.5.1 EMEA Cancer Targeted Therapy Market Status and Trend 2013-2023
1.5.2 Regional Cancer Targeted Therapy Market Status and Trend 2013-2023
CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Status of Cancer Targeted Therapy in EMEA 2013-2017
2.2 Consumption Market of Cancer Targeted Therapy in EMEA by Regions
2.2.1 Consumption Volume of Cancer Targeted Therapy in EMEA by Regions
2.2.2 Revenue of Cancer Targeted Therapy in EMEA by Regions
2.3 Market Analysis of Cancer Targeted Therapy in EMEA by Regions
2.3.1 Market Analysis of Cancer Targeted Therapy in Europe 2013-2017
2.3.2 Market Analysis of Cancer Targeted Therapy in Middle East 2013-2017
2.3.3 Market Analysis of Cancer Targeted Therapy in Africa 2013-2017
2.4 Market Development Forecast of Cancer Targeted Therapy in EMEA 2018-2023
2.4.1 Market Development Forecast of Cancer Targeted Therapy in EMEA 2018-2023
2.4.2 Market Development Forecast of Cancer Targeted Therapy by Regions 2018-2023
CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES
3.1 Whole EMEA Market Status by Types
3.1.1 Consumption Volume of Cancer Targeted Therapy in EMEA by Types
3.1.2 Revenue of Cancer Targeted Therapy in EMEA by Types
3.2 EMEA Market Status by Types in Major Countries
3.2.1 Market Status by Types in Europe
3.2.2 Market Status by Types in Middle East
3.2.3 Market Status by Types in Africa
3.3 Market Forecast of Cancer Targeted Therapy in EMEA by Types
CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Demand Volume of Cancer Targeted Therapy in EMEA by Downstream Industry
4.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Major Countries
4.2.1 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Europe
4.2.2 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Middle East
4.2.3 Demand Volume of Cancer Targeted Therapy by Downstream Industry in Africa
4.3 Market Forecast of Cancer Targeted Therapy in EMEA by Downstream Industry
CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF CANCER TARGETED THERAPY
5.1 EMEA Economy Situation and Trend Overview
5.2 Cancer Targeted Therapy Downstream Industry Situation and Trend Overview
CHAPTER 6 CANCER TARGETED THERAPY MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA
6.1 Sales Volume of Cancer Targeted Therapy in EMEA by Major Players
6.2 Revenue of Cancer Targeted Therapy in EMEA by Major Players
6.3 Basic Information of Cancer Targeted Therapy by Major Players
6.3.1 Headquarters Location and Established Time of Cancer Targeted Therapy Major Players
6.3.2 Employees and Revenue Level of Cancer Targeted Therapy Major Players
6.4 Market Competition News and Trend
6.4.1 Merger, Consolidation or Acquisition News
6.4.2 Investment or Disinvestment News
6.4.3 New Product Development and Launch
CHAPTER 7 CANCER TARGETED THERAPY MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
7.1 Advaxis
7.1.1 Company profile
7.1.2 Representative Cancer Targeted Therapy Product
7.1.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Advaxis
7.2 Bind Therapeutics
7.2.1 Company profile
7.2.2 Representative Cancer Targeted Therapy Product
7.2.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bind Therapeutics
7.3 Boehringer Ingelheim
7.3.1 Company profile
7.3.2 Representative Cancer Targeted Therapy Product
7.3.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
7.4 Bristol Mayer Squibb
7.4.1 Company profile
7.4.2 Representative Cancer Targeted Therapy Product
7.4.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Bristol Mayer Squibb
7.5 Celldex Therapeutics
7.5.1 Company profile
7.5.2 Representative Cancer Targeted Therapy Product
7.5.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Celldex Therapeutics
7.6 Dendreon Corporation
7.6.1 Company profile
7.6.2 Representative Cancer Targeted Therapy Product
7.6.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Dendreon Corporation
7.7 Eli Lily
7.7.1 Company profile
7.7.2 Representative Cancer Targeted Therapy Product
7.7.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Eli Lily
7.8 GalaxoSmithKline
7.8.1 Company profile
7.8.2 Representative Cancer Targeted Therapy Product
7.8.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of GalaxoSmithKline
7.9 Galena Biopharma
7.9.1 Company profile
7.9.2 Representative Cancer Targeted Therapy Product
7.9.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Galena Biopharma
7.10 Genetech
7.10.1 Company profile
7.10.2 Representative Cancer Targeted Therapy Product
7.10.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Genetech
7.11 ImmunoCellular Therapeutics
7.11.1 Company profile
7.11.2 Representative Cancer Targeted Therapy Product
7.11.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoCellular Therapeutics
7.12 ImmunoGen
7.12.1 Company profile
7.12.2 Representative Cancer Targeted Therapy Product
7.12.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of ImmunoGen
7.13 Inovio Pharmaceuticals
7.13.1 Company profile
7.13.2 Representative Cancer Targeted Therapy Product
7.13.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Inovio Pharmaceuticals
7.14 Johnson & Johnson
7.14.1 Company profile
7.14.2 Representative Cancer Targeted Therapy Product
7.14.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of Johnson & Johnson
7.15 NeoStem Oncology
7.15.1 Company profile
7.15.2 Representative Cancer Targeted Therapy Product
7.15.3 Cancer Targeted Therapy Sales, Revenue, Price and Gross Margin of NeoStem Oncology
7.16 NewLink Genetics
7.17 Northwest Biotherapeutics
7.18 Merck
7.19 Novartis
7.20 Peregrine Pharmaceuticals
7.21 Pfizer
7.22 Roche
7.23 Sanofi
7.24 Seattle Genetics
7.25 Teva
CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF CANCER TARGETED THERAPY
8.1 Industry Chain of Cancer Targeted Therapy
8.2 Upstream Market and Representative Companies Analysis
8.3 Downstream Market and Representative Companies Analysis
CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF CANCER TARGETED THERAPY
9.1 Cost Structure Analysis of Cancer Targeted Therapy
9.2 Raw Materials Cost Analysis of Cancer Targeted Therapy
9.3 Labor Cost Analysis of Cancer Targeted Therapy
9.4 Manufacturing Expenses Analysis of Cancer Targeted Therapy
CHAPTER 10 MARKETING STATUS ANALYSIS OF CANCER TARGETED THERAPY
10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
10.2.1 Pricing Strategy
10.2.2 Brand Strategy
10.2.3 Target Client
10.3 Distributors/Traders List
CHAPTER 11 REPORT CONCLUSION
CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Reference
